Cabaletta Bio Inc is a pioneering biotech firm dedicated to advancing engineered T cell therapies for autoimmune diseases. With a focus on B cell-mediated conditions, its flagship project, DSG3-CAART, targets the autoimmune skin disease mucosal pemphigus vulgaris and is currently in Phase I trials. The company's pipeline also explores treatments for myasthenia gravis and severe autoimmune diseases, among others. Founded in 2017 and based in Philadelphia, Cabaletta Bio collaborates with notable institutions like the University of Pennsylvania and the Children’s Hospital of Philadelphia.
A single analyst note sent Kyverna Therapeutics tumbling despite a clinical milestone that had investors cheering just weeks ago, and the question now is whether the selloff marks a buying opportunity or…
